<p>According to the latest report published by Credence Research, Inc. “Liquid Biopsy: Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the liquid biopsy market was valued at USD 1,881.9 Mn in 2015, and is expected to reach USD 10,850.3 Mn by 2022, expanding at a CAGR of 24.7% from 2016 to 2022.</p> <p><strong>Browse the full report Liquid Biopsy: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 report at <a href="http://www.credenceresearch.com/report/liquid-biopsy-market" target="_blank" rel="nofollow">http://www.credenceresearch.com/report/liquid-biopsy-market</a></strong></p> <p><strong>Market Insights</strong><br /> In the past, tissue samples extracted through biopsy were evaluated to detected malignancy. However, some micrographs delivered inconsistent and ambiguous results, thus demanding repeated procedure. The advent of molecular diagnostics and next generation sequencing offered pathologists with a powerful tool for efficient diagnosis. Even with such advances, cancer diagnosis still remained subject to the limitation of availability of biopsied tissue, which further posed a challenge in case of monitoring therapy success monitoring. The eventual advent of liquid biopsy however, overcame this constraint by efficiently employing precise circulating tumor cells (CTCs) detection and isolation.</p> <p><strong>Browse All Reports of This Category @ <a href="http://www.credenceresearch.com/industry/pharmaceuticals-market" target="_blank" rel="nofollow">http://www.credenceresearch.com/industry/pharmaceuticals-market</a></strong></p> <p>In the recent period, the range of liquid biopsy tools has expanded to incorporation of circulating tumor DNA (ctDNA) and extracellular vesicles (EVs). ctDNA contains a small fraction of the patient's cell free DNA; it can be readily evaluated for genetic inconsistency using target amplification and sequencing tools. In addition, EVs is currently the latest addition to liquid biopsy portfolio. EVs provide easy access to biomolecule subsets present in whole cells. EVs based technology is focused on identifying mutations in mRNA.</p> <p>Extensive research is being taken place in the recent years on creating sophisticated analytical tools for analysis of cancer cells for detecting genetic variation at low allele frequency. CTCs are first of such units of liquid biopsy. However, advent of easy isolation of cell-free DNA has provided vital insights that move a step ahead to that of CTCs. The latest tools of EVs analysis are rapidly gaining importance on the basis of their potential ability of identifying genetic variation. The latest CTC technologies employ EpCAM protein for immunocapture, however this tool demonstrate reduced expression during epithelial to mesenchymal transition. Other isolation techniques are heavily dependent on cell size, cellular behavior in electric fields, morphology and deformability. Scarcity of CTCs in blood has urged researchers to develop evolved methods for obtaining molecular information from single cells, thus increasing their potential use in therapy monitoring.</p> <p><strong>Blog URL - <a href="http://www.mobilecomputingtoday.co.uk/3497/global-liquid-biopsy-market-reach-worth-usd-10850-3-2022-preference-non-invasive-diagnostics-game-changers-credence-research/" target="_blank" rel="nofollow">http://www.mobilecomputingtoday.co.uk/3497/global-liquid-biopsy-market-reach-worth-usd-10850-3-2022-preference-non-invasive-diagnostics-game-changers-credence-research/</a></strong></p> <p>As the commercial interest in this field is on the rise, several large diagnostics and medical technologies companies have ventured in this market. Moreover, there is also a significant rise in the number of startups specializing in the field. Industry giants are striking deals with pharma and biotech companies to expand application areas of liquid biopsy.</p> <p><strong>About Credence Research:</strong><br /> Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.</p> <p><strong>Who we are</strong><br /> Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.<br /> Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa. <br /> Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.</p> <p><strong>What we do</strong><br /> We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.</p> <p>No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.</p> <p><strong>For More Information, Visit: <a href="http://www.credenceresearch.com/" target="_blank" rel="nofollow">Credence Research</a></strong></p> <p><strong>Media Contact</strong><br /> Company Name: Credence Research<br /> Contact Person: Chris Smith, <br /> Designation: Global Sales Manager<br /> Phone: 1-800-361-8290 FREE FREE<br /> Address: 105 N 1st ST #429, SAN JOSE, <br /> CA 95103<br /> E-mail: sales@credenceresearch.com</p
Topics
